The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 262
- 试验地点
- 1
- 主要终点
- Difference of overall survival according to p-AKT status in malignant lymphoma
研究概览
简要总结
PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.
详细描述
Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B [PKB]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers.
However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 17 Years 至 90 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification;
- •the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.
排除标准
- •Primary central nervous system lymphoma was excluded in this study
结局指标
主要结局
Difference of overall survival according to p-AKT status in malignant lymphoma
时间窗: study entry
次要结局
- Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)(study entry)
研究者
Won Seog Kim
Professor
Samsung Medical Center